While human COPD trials have not universally confirmed MMP-9 suppression (e.g., studies showing no change in plasma MMP-9 despite therapy), the convergence of mechanistic and disease-model data supports a role for PDE4 inhibitors in dampening MMP-9-driven tissue injury within respiratory and inflammatory settings. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.